Association of Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2021 Jan 15

PMID 33447072

Citations 5

Authors

Pornpen Srisawasdi

Punyanuch Rodcharoen

Somlak Vanavanan

Anchalee Chittamma

Chonlaphat Sukasem

Chalitpon Na Nakorn

Charungthai Dejthevaporn

Martin H Kroll

Affiliations

Soon will be listed here.

Abstract

Objective: Patients treated with statins for dyslipidemia may still have a residual risk of atherosclerotic cardiovascular disease (ASCVD). To determine whether genetic variants in the cholesteryl ester transport protein (CETP), rs3764261 (C>A), rs708272 (G>A), and rs12149545 (G>A) affect ASCVD risk, we studied the association of these variants with dyslipidemia in statin-treated patients.

Patients And Methods: We included 299 adult Thai patients treated with a statin (95 men and 204 women). Genotyping was performed by conducting a TaqMan real-time polymerase chain reaction-based analysis. We used logistic regression models adjusted for potential confounders of age, body mass index, blood pressure, insulin resistance, and statin dosage to analyze the association between variants and atherogenic lipoprotein patterns.

Results: polymorphisms of rs3764261 and rs708272, but not rs12149545, were significantly associated with high-density lipoprotein cholesterol (HDL-C), apoA-I, triglycerides, very low-density lipoprotein (VLDL)-C, and large LDL (LDL1-C) levels as well as mean LDL particle size (all < 0.020). However, no significant difference was observed in total cholesterol, LDL-C, or apoB levels by variants. Regardless of sex, the combination of rs3764261 (CC genotype) and rs708272 (GG or GA genotypes) showed a stronger association with atherogenic dyslipidemia, including features of decreased HDL-C, elevated triglycerides, and LDL subclass pattern B (odds ratio [OR] = 2.99, 95% confidence interval [CI]: 1.78-5.02) compared with the single variant rs3764261 (OR = 2.11, 95% CI: 1.27-3.50) or rs708272 (OR = 2.12, 95% CI: 1.29-3.49).

Conclusion: The polymorphisms of rs3764261 (CC genotype) and rs708272 (GG and GA genotypes) may have a higher susceptibility to atherogenic dyslipidemia. Testing for rs3764261 and rs708272 may serve as a surrogate marker for lipid management in statin-treated patients, which may help individualize treatment for reducing the residual risk of ASCVD.

Citing Articles

Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.

Ponikowska M, Di Domenico P, Bolli A, Busby G, Perez E, Botta G Nutrients. 2025; 17(5).

PMID: 40077796 PMC: 11901995. DOI: 10.3390/nu17050926.

Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to Lipid Profiles and Cardiovascular Diseases: An Update.

Dabravolski S, Orekhov N, Melnichenko A, Sukhorukov V, Popov M, Orekhov A Curr Pharm Des. 2024; 30(10):742-756.

PMID: 38425105 DOI: 10.2174/0113816128284695240219093612.

Gender Differences in the Association between Cholesteryl Esters Transfer Protein Polymorphism (rs708272) and Plasma Lipid Levels in Hyperlipidaemic Participants at Hospital Universiti Sains Malaysia.

Shamsudin A, Bakar N Malays J Med Sci. 2023; 30(2):96-110.

PMID: 37102051 PMC: 10125239. DOI: 10.21315/mjms2023.30.2.9.

Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component?.

Butnariu L, Florea L, Badescu M, Tarca E, Costache I, Gorduza E Life (Basel). 2022; 12(6).

PMID: 35743896 PMC: 9225091. DOI: 10.3390/life12060865.

Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.

Vanwong N, Tipnoppanon S, Na Nakorn C, Srisawasdi P, Rodcharoen P, Medhasi S Pharmgenomics Pers Med. 2022; 15:119-130.

PMID: 35210819 PMC: 8860396. DOI: 10.2147/PGPM.S346093.

References

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

Ference B, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A . Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25):2631-9. DOI: 10.1016/j.jacc.2012.09.017. View

Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View

Lu Y, Tayebi N, Li H, Saha N, Yang H, Heng C . Association of CETP Taq1B and -629C > A polymorphisms with coronary artery disease and lipid levels in the multi-ethnic Singaporean population. Lipids Health Dis. 2013; 12:85. PMC: 3699414. DOI: 10.1186/1476-511X-12-85. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841):581-90. PMC: 3437972. DOI: 10.1016/S0140-6736(12)60367-5. View

Carlquist J, Muhlestein J, Horne B, Hart N, Bair T, Molhuizen H . The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J. 2003; 146(6):1007-14. DOI: 10.1016/S0002-8703(03)00501-5. View

Whiting B, Anderson J, Muhlestein J, Horne B, Bair T, Pearson R . Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J. 2005; 150(2):243-50. DOI: 10.1016/j.ahj.2004.08.034. View

Kuivenhoven J, Jukema J, Zwinderman A, de Knijff P, McPherson R, Bruschke A . The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998; 338(2):86-93. DOI: 10.1056/NEJM199801083380203. View

10.

Ridker P, Pradhan A, MacFadyen J, Libby P, Glynn R . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380(9841):565-71. PMC: 3774022. DOI: 10.1016/S0140-6736(12)61190-8. View

11.

Rana J, Liu J, Moffet H, Solomon M, Go A, Jaffe M . Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. Am J Cardiol. 2015; 116(11):1700-4. DOI: 10.1016/j.amjcard.2015.08.039. View

12.

Barter P, Brewer Jr H, Chapman M, Hennekens C, Rader D, Tall A . Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003; 23(2):160-7. DOI: 10.1161/01.atv.0000054658.91146.64. View

13.

Cai G, Shi G, Huang Z . Gender specific effect of CETP rs708272 polymorphism on lipid and atherogenic index of plasma levels but not on the risk of coronary artery disease: A case-control study. Medicine (Baltimore). 2018; 97(49):e13514. PMC: 6310534. DOI: 10.1097/MD.0000000000013514. View

14.

Niu W, Qi Y . Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis. Circ Cardiovasc Genet. 2015; 8(1):114-21. DOI: 10.1161/CIRCGENETICS.114.000748. View

15.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

16.

Nichols G, Philip S, Reynolds K, Granowitz C, Fazio S . Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2018; 21(2):366-371. PMC: 6587847. DOI: 10.1111/dom.13537. View

17.

Chapman M, Orsoni A, Robillard P, Therond P, Giral P . Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. J Clin Lipidol. 2018; 12(3):784-800.e4. DOI: 10.1016/j.jacl.2018.02.001. View

18.

Ference B, Kastelein J, Ginsberg H, Chapman M, Nicholls S, Ray K . Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA. 2017; 318(10):947-956. PMC: 5710502. DOI: 10.1001/jama.2017.11467. View

19.

Kooner J, Chambers J, Aguilar-Salinas C, Hinds D, Hyde C, Warnes G . Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet. 2008; 40(2):149-51. DOI: 10.1038/ng.2007.61. View

20.

Blauw L, Li-Gao R, Noordam R, de Mutsert R, Trompet S, Berbee J . CETP (Cholesteryl Ester Transfer Protein) Concentration: A Genome-Wide Association Study Followed by Mendelian Randomization on Coronary Artery Disease. Circ Genom Precis Med. 2018; 11(5):e002034. DOI: 10.1161/CIRCGEN.117.002034. View